Biosimilars in the Evolving Cancer Care Landscape: Experts Address Current Questions, Controversies, and Impact on Clinical Practice

Orlando, FL US
March 23, 2018

The goal of this activity is to increase participants’ knowledge of and competence in describing the regulatory approval process for biosimilars and effectively using them to replace reference products in the daily practice of treating cancer.

Target Audience

This program is intended for medical oncologists and other healthcare professionals, including nurses, nurse practitioners, physician assistants, and pharmacists, who provide medical care for patients with cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe differences between biosimilars and reference biologics in terms of their structure, function, regulatory requirements, and data demonstrating biosimilarity.
  • Discuss key clinical considerations associated with the use of biosimilars in the treatment of cancer, including extrapolation, immunogenicity, pharmacovigilance, and patient communication.
  • Consider current and emerging efficacy and safety data for biosimilar agents in the care of patients with cancer.
  • Manage patients receiving biosimilars, guided by recent experiences and emerging clinical trial data regarding their safety and efficacy.
  • Identify key strategies to counsel and communicate the impact biosimilars may have on a patient’s treatment plan.
Additional information

Jointly provided by NCCN and Clinical Care Options, LLC.


This activity is supported by educational funding provided by Amgen. This activity is supported by educational grants from Pfizer Inc. and Sandoz Inc., a Novartis Division.

Course summary
Available credit: 
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Course opens: 
Course expires: 
Event starts: 
03/23/2018 - 6:45am EDT
Event ends: 
03/23/2018 - 7:45am EDT
Rosen Shingle Creek
9939 Universal Blvd
Panzacola Ballroom F
Orlando, FL 32819
United States

Andrew D. Zelenetz, MD, PhD
Medical Director, Quality Informatics
Attending Physician, Lymphoma Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill-Cornell Medical College
New York, New York

Jeffrey Crawford, MD
George Barth Geller Professor of Medicine
Duke University
Co-Director, Solid Tumor Therapeutics Program
Duke Cancer Institute
Durham, North Carolina

Lee Schwartzberg, MD, FACP
Executive Director, West Cancer Center
Chief, Division of Hematology/Oncology
University of Tennessee Health Science Center
Professor of Medicine, Division of Hematology/Oncology
University of Tennessee Health Science Center
Memphis, Tennessee


Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of National Comprehensive Cancer Network (NCCN) and Clinical Care Options, LLC. NCCN is accredited by the ACCME to provide continuing medical education for physicians.

NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.0 hour of Category 1 credit for completing this activity.

National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

NCCN designates this educational activity for a maximum of 1.0 contact hour.


National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: 0836-9999-18-032-L01-P

Available Credit

  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation


Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Reader or other PDF reader software for certificate viewing/printing